Method for treating acute myeloid leukemia or acute lymphoblastic leukemia using a pharmaceutical composition comprising a thienotriazolodiazepine compound

摘要

A pharmaceutically acceptable amount of the following formula (1): [wherein R1 is alkyl having 1 to 4 carbon atoms, and R2 is substituted with a hydrogen atom; a halogen atom; or a halogen atom or a hydroxyl group. R3 is optionally substituted with a halogen atom; a halogen atom, an alkyl having 1 to 4 carbon atoms, an alkoxy having 1 to 4 carbon atoms, or cyano. -NR5- (CH2) m-R6 (wherein R5 is a hydrogen atom or alkyl having 1 to 4 carbon atoms, m is an integer of 0 to 4, and R6 is halogen) Phenyl or pyridyl optionally substituted with atoms.); Or —NR 7 —CO— (CH 2) n —R 8 (wherein R 7 is a hydrogen atom or alkyl having 1 to 4 carbon atoms, n is an integer from 0 to 2 R8 is phenyl or pyridyl optionally substituted with a halogen atom, and R4 is-(CH2) a-CO-NH-R9 (wherein, a is an integer of 1 to 4). R9 is alkyl having 1 to 4 carbon atoms; hydroxyalkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; or alkyl having 1 to 4 carbon atoms; 4 is an alkoxy having 4 carbon atoms, phenyl or pyridyl optionally substituted by an amino or hydroxyl group.) Or-(CH2) b-COOR10 (wherein b is an integer of 1 to 4 and R10 is , Alkyl having 1 to 4 carbon atoms.). A method for treating acute myeloid leukemia or acute lymphoblastic leukemia in a mammal, comprising a step of administering a thienotriazolodiazepine compound represented by the formula: . [Selection figure] None